BioAegis Therapeutics, Inc.

BioAegis Therapeutics, Inc. specializes in developing innovative therapies for inflammatory diseases, focusing on its lead product, recombinant human plasma gelsolin, to enhance immune response and combat various conditions. Founded in 2011, BioAegis Therapeutics, Inc. is based in Brunswick, US, and focuses on therapies for inflammatory diseases.

The company has executed 5 deals, with its most recent funding round occurring on December 23, 2021, raising USD 22. 00 mn. The CEO is Susan Levinson, and the company was founded by Steven Cordovano. BioAegis Therapeutics specializes in the development of therapies targeting inflammatory diseases, focusing primarily on its flagship product, recombinant human plasma gelsolin (rhu-pGSN).

This protein is engineered to restore normal levels of plasma gelsolin, which are often depleted in various inflammatory conditions. rhu-pGSN functions by modulating the innate immune response, thereby enhancing immune cell efficacy in combating infections and controlling excessive inflammation. The company aims to address unmet medical needs across multiple disease applications, including acute respiratory distress syndrome (ARDS) and other chronic inflammatory diseases. The products are primarily positioned for use in clinical settings, catering to hospitals, healthcare providers, and research institutions across North America, Europe, and potentially expanding into Asia and other global markets.

BioAegis Therapeutics generates revenue through strategic partnerships, clinical trial collaborations, and potentially through direct licensing agreements for its recombinant human plasma gelsolin product. The company’s revenue model involves B2B transactions, where healthcare organizations and research institutions procure rhu-pGSN for clinical use and research applications. Given the therapeutic nature of the product, transactions may be structured around trial-based agreements and subsequent supply contracts following successful validation of efficacy. The pricing framework aligns with industry standards for biologics and recombinant proteins, focusing on cost-effectiveness while ensuring accessibility for hospitals and healthcare systems.

The company's intellectual property portfolio and extensive clinical collaborations enhance its market position and potential revenue streams. Following its recent funding round on December 23, 2021, where BioAegis Therapeutics, Inc. raised USD 22. 00 mn, the company plans to accelerate the expansion of its therapeutic pipeline, including new indications.

BioAegis is advancing its Phase 2 program in the United States with severe pneumonia and is also set to enhance production capabilities to support the development of secondary indications. The company is looking to expand its market reach into Asia and other global regions.